2197.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 11:08):

Stats
Dzisiejszy wolumen	8.03M
Średni wolumen	1.44M
Kapitalizacja rynkowa	564.19M
EPS	HKD0 ( 2024-03-25 )
Następna data zysków	( HKD0 ) 2024-05-29
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-3.62
ATR14	HKD0.00200 (0.46%)

Wolumen Korelacja

Długi: 0.05 (neutral)

Krótki: -0.05 (neutral)

Signal:(65.15) Neutral

Clover Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clover Korelacja - Waluta/Towar

0.72
( moderate )

0.83
( strong )

0.00
( neutral )

-0.79
( moderate negative )

Clover Finanse

Annual	2023
Przychody:	HKD39.26M
Zysk brutto:	HKD24.24M (61.75 %)
EPS:	HKD-0.110

FY	2023
Przychody:	HKD39.26M
Zysk brutto:	HKD24.24M (61.75 %)
EPS:	HKD-0.110

FY	2022
Przychody:	HKD0
Zysk brutto:	HKD-475.64M (0.00 %)
EPS:	HKD-2.22

FY	2021
Przychody:	HKD0.00
Zysk brutto:	HKD0.00 (0.00 %)
EPS:	HKD-5.19

Financial Reports:

No articles found.

Clover

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.